Your browser is no longer supported. Please, upgrade your browser.
PRQR ProQR Therapeutics N.V. monthly Stock Chart
PRQR [NASD]
ProQR Therapeutics N.V.
Index- P/E- EPS (ttm)-1.30 Insider Own20.00% Shs Outstand43.05M Perf Week-5.83%
Market Cap333.64M Forward P/E- EPS next Y-1.83 Insider Trans0.00% Shs Float37.05M Perf Month-6.85%
Income-49.60M PEG- EPS next Q-0.40 Inst Own66.50% Short Float5.89% Perf Quarter-36.84%
Sales5.90M P/S56.55 EPS this Y37.00% Inst Trans-2.52% Short Ratio12.53 Perf Half Y-43.18%
Book/sh2.02 P/B3.84 EPS next Y-11.50% ROA-42.40% Target Price29.16 Perf Year5.44%
Cash/sh2.13 P/C3.64 EPS next 5Y- ROE-51.50% 52W Range7.35 - 24.00 Perf YTD-50.89%
Dividend- P/FCF- EPS past 5Y-47.50% ROI-35.50% 52W High-67.71% Beta0.16
Dividend %- Quick Ratio9.50 Sales past 5Y118.40% Gross Margin- 52W Low5.44% ATR0.48
Employees119 Current Ratio9.50 Sales Q/Q-40.00% Oper. Margin- RSI (14)38.70 Volatility6.17% 6.40%
OptionableYes Debt/Eq0.15 EPS Q/Q-30.20% Profit Margin- Rel Volume0.44 Prev Close8.12
ShortableYes LT Debt/Eq0.15 EarningsAug 14 BMO Payout- Avg Volume174.03K Price7.75
Recom1.70 SMA20-9.90% SMA50-14.56% SMA200-42.08% Volume76,798 Change-4.56%
Mar-12-19Reiterated Chardan Capital Markets Buy $21 → $25
Dec-19-18Initiated RBC Capital Mkts Outperform
Nov-15-18Initiated Citigroup Buy $32
Sep-19-18Initiated Evercore ISI Outperform
Sep-26-17Reiterated JMP Securities Mkt Outperform $14 → $20
Jun-20-16Initiated Chardan Capital Markets Neutral $4.50
Oct-15-14Initiated Deutsche Bank Buy $32
Oct-13-14Initiated H.C. Wainwright Buy $40
Aug-14-19 12:18PM  Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study Zacks -8.05%
Aug-13-19 11:53AM  Mallinckrodt Enrolls First Patient in Liver Disease Study Zacks
Aug-12-19 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) GlobeNewswire
Aug-07-19 10:05AM  ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  ProQR Announces Financial Results for the Second Quarter of 2019 GlobeNewswire
Jul-29-19 07:00AM  European Medicines Agency Grants PRIME Access to ProQRs Sepofarsen for Lebers Congenital Amaurosis 10 GlobeNewswire
Jul-26-19 01:31PM  What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year? Simply Wall St.
Jul-02-19 07:00AM  ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July GlobeNewswire
Jun-29-19 05:34PM  Heres What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
Jun-03-19 07:00AM  ProQR to Present at the JMP Securities Life Sciences Conference GlobeNewswire
May-27-19 10:56AM  Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%? Simply Wall St.
May-15-19 07:00AM  ProQR to Present at the RBC Capital Markets Healthcare Conference GlobeNewswire
May-08-19 02:29PM  Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
08:45AM  ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:34AM  ProQR: 1Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the First Quarter of 2019 GlobeNewswire
Apr-22-19 07:00AM  ProQR to Present at Three Scientific Conferences in April GlobeNewswire
Apr-18-19 07:00AM  ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board GlobeNewswire
07:00AM  ProQR Announces Annual Meeting of Shareholders GlobeNewswire
Apr-16-19 07:26PM  ProQR Initiates Dosing in Phase II/III Eye Disorder Study Zacks -7.38%
Apr-15-19 07:00AM  ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 GlobeNewswire
Apr-01-19 07:00AM  ProQR to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-26-19 04:01PM  ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership GlobeNewswire
Mar-11-19 08:00AM  ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 GlobeNewswire
Mar-05-19 07:00AM  ProQR to Present at Cowen Health Care Conference GlobeNewswire
Feb-28-19 09:50AM  Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks
Feb-27-19 07:00AM  ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
Jan-29-19 10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
08:30AM  ProQR Announces ProQR Vision 2023 Strategy at its Annual R&D Day GlobeNewswire
Jan-22-19 10:44AM  Should You Worry About ProQR Therapeutics N.V.s (NASDAQ:PRQR) CEO Salary Level? Simply Wall St.
Jan-07-19 07:00AM  ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Lebers Congenital Amaurosis 10 GlobeNewswire
Jan-03-19 09:51AM  Company News For Jan 3, 2019 Zacks
07:00AM  ProQR to Host R&D Day in New York on January 29 GlobeNewswire
Jan-02-19 11:10AM  Best Sector of 2018 and its Hit ETFs & Stocks Zacks +10.77%
07:00AM  ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 GlobeNewswire
Dec-24-18 07:00AM  ProQR Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-23-18 04:31AM  Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds? Insider Monkey
Dec-17-18 11:52AM  ProQR Announces Publication in Nature Medicine of QR-110 Data for Lebers Congenital Amaurosis 10 GlobeNewswire
Dec-13-18 07:00AM  ProQR Announces Strategic Changes to the Management Team and Key New Hires GlobeNewswire
Dec-10-18 07:00AM  ProQR Receives 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 GlobeNewswire -5.11%
Dec-04-18 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients GlobeNewswire
Nov-20-18 07:00AM  ProQR to Present at the Evercore ISI HealthConX Conference GlobeNewswire
Nov-16-18 08:55AM  Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-07-18 08:45AM  ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates Zacks -5.23%
07:37AM  ProQR: 3Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the Third Quarter of 2018 GlobeNewswire
Oct-31-18 07:00AM  ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference GlobeNewswire
Oct-29-18 07:33AM  ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals GlobeNewswire
Oct-16-18 02:39PM  Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR) Simply Wall St.
Oct-02-18 07:00AM  ProQR to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Sep-24-18 07:00AM  ProQR Announces Presentations at the OTS Annual Meeting GlobeNewswire
Sep-12-18 10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks -14.35%
Sep-11-18 04:01PM  ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +15.82%
Sep-10-18 04:55PM  Why ProQR Therapeutics N.V. Is Soaring Again Today Motley Fool +18.04%
Sep-08-18 07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 04:21AM  ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares GlobeNewswire
Sep-06-18 11:20AM  ProQR Up More Than 120% on Favorable Eye Disorder Study Data Zacks -8.26%
08:00AM  Todays Research Reports on Stocks to Watch: ProQR Therapeutics and Sangamo Therapeutics ACCESSWIRE
Sep-05-18 04:01PM  ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares GlobeNewswire +120.75%
12:49PM  Here's Why ProQR Therapeutics N.V. Is Skyrocketing Today Motley Fool
11:20AM  Biotech Stocks & Marijuana Stocks Moving Higher on Wednesday ACCESSWIRE
09:39AM  ProQR's stock rockets to pace all gainers after upbeat drug trial results MarketWatch
09:16AM  ProQR soars as childhood blindness drug succeeds in early trial Reuters
09:15AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
04:00AM  ProQR drug for rare childhood blindness succeeds in early trial Reuters
04:00AM  ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial GlobeNewswire
Aug-15-18 07:00AM  ProQR to Present Interim Phase 1/2 Results for QR-110 in Lebers Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th GlobeNewswire
Aug-08-18 09:15AM  ProQR: 2Q Earnings Snapshot Associated Press +5.67%
07:00AM  ProQR Announces Financial Results for the Second Quarter of 2018 GlobeNewswire
Aug-01-18 07:00AM  ProQR Announces Publication on QR-110 for Lebers Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids GlobeNewswire
Jul-12-18 07:00AM  ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July GlobeNewswire +6.98%
Jun-28-18 07:00AM  ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa GlobeNewswire
Jun-14-18 07:00AM  ProQR to Present at the JMP Life Sciences Conference GlobeNewswire
Jun-12-18 07:00AM  ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa GlobeNewswire
Jun-08-18 07:20AM  Wired News Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinsons Treatment ACCESSWIRE
Jun-04-18 07:00AM  ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference GlobeNewswire +14.78%
May-23-18 07:00AM  ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board GlobeNewswire +10.00%
May-09-18 07:46AM  ProQR: 1Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Results for the First Quarter of 2018 GlobeNewswire
Apr-30-18 07:00AM  ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB GlobeNewswire
Apr-23-18 07:00AM  ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO GlobeNewswire
Apr-18-18 09:57AM  Will ProQR Therapeutics (PRQR) Continue to Surge Higher? Zacks
Apr-10-18 07:00AM  ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology GlobeNewswire
Apr-03-18 07:00AM  ProQR to Present at Two Upcoming Conferences GlobeNewswire
Mar-05-18 07:00AM  ProQR to Present at Upcoming Investor Conference GlobeNewswire
Feb-28-18 07:45AM  ProQR reports 4Q loss Associated Press
07:00AM  ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update GlobeNewswire
Feb-27-18 07:00AM  ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer GlobeNewswire
Feb-26-18 06:43AM  Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
Feb-12-18 07:00AM  Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQRs candidate QR-421a for Usher syndrome type 2A GlobeNewswire
Feb-06-18 07:00AM  ProQR to Present at Upcoming Scientific Meeting and Investor Conference GlobeNewswire
Jan-08-18 07:00AM  ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQRs Axiomer® technology GlobeNewswire
Dec-27-17 07:00AM  ProQR Announces Extraordinary General Meeting of Shareholders GlobeNewswire
Nov-29-17 07:00AM  ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa GlobeNewswire
Nov-21-17 07:00AM  ProQR to Present at the Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-20-17 07:11AM  ProQR reports 3Q loss Associated Press
07:00AM  ProQR Announces Results for the Third Quarter of 2017 GlobeNewswire
Nov-14-17 07:44AM  ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares GlobeNewswire -13.67%
Nov-13-17 04:01PM  ProQR Announces Proposed Public Offering of Ordinary Shares GlobeNewswire
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.